Navigation Links
Merck Announces Plans for Licensing Atripla Widely in Developing World

Merck & Co is seeking to register its three-in-one fixed dose combination Atripla in 66 developing countries, in addition to seeking// World Health Organization prequalification for the product, the company announced on Friday.

Atripla, which is a single tablet containing a daily dose of efavirenz, tenofovir and emtricitabine, will be priced at $613 a year for least developed countries and higher prevalence middle income countries (>1% HIV prevalence), and $1032 a year for other middle-income countries that qualify for a discounted price.

Atripla will be sold in developing countries as a white tablet in order to differentiate it from the salmon-pink tablet sold in the United States, in order to reduce the risk of diversion of product from developing countries.

Atripla is a collaboration between Merck, the license holder for efavirenz outside the US and western Europe, and Gilead, the license holder of tenofovir and emtricitabine. In contrast to Gilead's policy with tenofovir, where the company has granted voluntary licenses in India and South Africa, Atripla commercialisation will remain in the hands of the patent holders. This is likely to prevent any significant competitive pressure on the price of the product, since once licenses are granted, competition from generic versions of this fixed dose combination will be impossible without the granting of compulsory licenses for rival versions.

Although Merck will be able to import Atripla into eleven countries on the basis of US Food and Drug Administration registration, licensing in other countries may take several years in some cases owing to lack of regulatory agency capacity. Tenofovir, one of the components of Atripla, remains unlicensed in South Africa despite the grant of a voluntary license for the product to South African manufacturer Aspen in 2004. According to the Treatment Action Campaign, Aspen’s version of tenofovir was already under fast track review by South Africa’s Medicines Control Council in June 2006.

The combination of efavirenz, tenofovir and emtricitabine has been recommended by the World Health Organization as a preferred first-line combination wherever it is available, because of the reduced risk of toxicity when compared to a stavudine (d4T)-based regimen.

Source-Bio-Bio Technology
SR
'"/>




Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia ... 1, 2017. The name change aligns the entire company with its existing ... care quality. , “We are very proud of the achievements associated with the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , a ... other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to ... president of sales. , Litsinger joined Mirixa in 2008 after serving as ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)...  A new study by a pair of Geisinger ... therapy to treat chronic pain is not only ineffective, ... consequences, including death. Palliative care physicians ... , M.D., authored the study which provides a review ... study was published in the December 2016 edition of ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... world,s largest abstract and citation database of peer-reviewed literature, providing the ... 5,000 publishers. The new set of metrics will improve decisions on ... adjust a journal,s editorial strategy. ... , CiteScore metrics comprise ...
Breaking Medicine Technology: